WHO puts new neglected tropical disease requests on hold during criteria review
The World Health Organization has paused consideration of requests to add new diseases to its neglected tropical diseases list while it reviews the criteria and process used to decide what belongs there. The decision came from the Strategic and Technical Advisory Group for Neglected Tropical Diseases after extensive discussion at its 20th meeting in August.
The pause is temporary, but it is consequential. The NTD label carries political weight, shapes research priorities, and helps direct scarce resources toward conditions that disproportionately affect underserved populations. When the definition of the category itself is under review, the policy mechanics matter almost as much as the diseases being considered.
A framework built in 2016 is being reassessed
The current criteria for inclusion were established in 2016 and have not had a formal reassessment since then. In the years that followed, the list has expanded to 21 diseases and disease groups, with noma the most recent addition.
STAG-NTD accepted that the existing framework created a more structured and transparent way to assess applications. Even so, members raised fundamental questions about whether the rules still fit WHO’s broader mandate, current priorities, and resource environment. Public health classifications are not static academic labels; they determine which diseases receive sustained attention, technical guidance, and advocacy. When a category grows without a corresponding review of its governing logic, tension builds between ambition and operational capacity.
A quiet problem sits inside that expansion.
The list has no formal mechanism for reviewing or removing diseases once they have been added.
WHO’s responsibilities after listing need clearer definition
One of the sharpest concerns centered on what happens after a disease is placed on the NTD list. At present, there is no formal policy defining WHO’s responsibilities once inclusion is approved, and there is no explicit guidance on the human or financial resources that may be required to support those responsibilities.
That gap is not administrative trivia. If a disease enters the portfolio, expectations quickly follow: coordination, technical support, advocacy, surveillance alignment, research attention, and the possibility of downstream programmatic commitments. Without clearer rules, each new inclusion can alter workload and resource needs in ways that are difficult to predict or justify. For an organization operating under finite staffing and budget constraints, clarity about scope is a prerequisite for credibility.
Members judged those issues essential to resolve before the portfolio expands further. The review is intended to address the foundations of inclusion, not to settle the status of any single disease by implication.
The pause is temporary, not a permanent gate
STAG-NTD recommended that consideration of new requests be suspended while the review is conducted independently of any individual application. The group was explicit that the pause should not be interpreted as a permanent restriction or as a verdict on any specific disease.
This distinction matters for countries, advocates, researchers, and patient groups that may have prepared submissions or are considering future requests. The hold is meant to preserve the integrity of the review process by preventing case-by-case decisions from being made under criteria that may soon change. In practical terms, WHO is stepping back from expansion until it has a clearer way to judge expansion.
The approach also signals concern about consistency. If applications are assessed under outdated rules while a newer framework is being developed, the process can appear uneven even when the underlying scientific case is strong. A temporary pause reduces the risk of locking in decisions that may no longer align with the revised criteria.
A structured review will shape the next round of decisions
WHO plans to carry out the review through a structured process that includes virtual consultations and written input from STAG-NTD members. Proposed revisions will be presented at the group’s next meeting, scheduled for 4–6 May 2027, when recommendations will be formulated.
Until that review is completed and any revised criteria are considered, requests for additional diseases will remain on hold. After the process is finished, WHO will communicate any changes to the criteria and process and then resume consideration of new submissions under the updated framework.
The timeline gives the organization room to revisit not only the wording of inclusion criteria but also the broader policy architecture around the NTD portfolio. In diseases that disproportionately affect vulnerable populations, classification can influence whether a condition attracts the advocacy it needs or remains outside the main international agenda. The review therefore has implications beyond nomenclature; it affects how global health attention is assigned and sustained.
Why the NTD list carries so much policy weight
The WHO NTD list is more than a directory. It helps mobilize political attention, guide public health action, shape research agendas, and facilitate resource mobilization for diseases that often persist in settings with limited infrastructure and limited negotiating power. For that reason, each addition can strengthen visibility for an overlooked condition, but it can also increase pressure on WHO to define what support comes with recognition.
A stronger framework may ultimately make the list more durable. Clear inclusion criteria, a process for reassessment, and explicit expectations after listing would reduce ambiguity for applicants and for WHO itself. The current pause suggests that the organization is trying to avoid making incremental decisions on top of an aging policy base.
The next test arrives in May 2027, when STAG-NTD is due to consider revised recommendations. Until then, new requests for inclusion will stay on hold while WHO determines how the NTD category should be governed in its next phase.